You are here: Home » Markets » News
Business Standard
Web Exclusive

After 100% gain since Nov, can the rally in Gland Pharma stock continue?

Gland's prospects remain strong, say analysts, as it has a robust pipeline of products with 50 pending Abbreviated New Drug Applications (ANDAs) and a healthy filing rate of 21 ANDAs in 9MFY21

Topics
Gland Pharma | Pharma stocks

Saloni Goel  |  New Delhi 

pharmacy, drugs, medicine, pharma companies, pharmaceuticals

has already doubled money for those investors who picked the stock at the time of its initial public offering (IPO) in November 2020. And now, the firm's March quarter results have convinced analysts of more upside as they see growth prospects for Gland going ahead.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, May 18 2021. 12:32 IST
RECOMMENDED FOR YOU
.